Keytruda (Pembroluzimab) Positive Results!

The pharmaceutical company MSD has shared positive overall survival results from a late stage study of its Keytruda regimen in early stage breast cancer. 

The phase 3 KEYNOTE-522 trial has been evaluating Keytruda  (Pembroluzimab) in combination with chemotherapy as a neoadjuvent  treatment before surgery, followed by Keytruda as a single agent adjuvent  treatment after surgery. 

This anti-PD-1 therapy is used for patients with high risk early-stage triple negative breast cancer.

Pembroluzimab